With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Lopinavir is a newly developed inhibitor of human immunodeficiency virus (HIV) protease that, when formulated with ritonavir, yields mean trough plasma lopinavir concentrations that are at least 75 ...

In a recent retrospective and observational cohort study published in The Lancet Infectious Diseases, researchers examine non-hospitalized adult patients with coronavirus disease 2019 (COVID-19) ...

The retrospective study evaluated outcomes in patients prescribed nirmatrelvir-ritonavir, as well as the management of drug interactions by clinical pharmacists prescribing the regimen. COVID-19 is ...

Thousands of patients were enrolled in the lopinavir/ritonavir arm of the WHO-led Solidarity Trial as well as a separate U.K.-led trial of those drugs. The Solidarity Trial was established by the WHO ...

The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the rapid outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has immensely affected the global healthcare ...

Darunavir is a new protease inhibitor (PI) active against wild-type and drug-resistant HIV-1 strains and has recently been approved for use in treatment-experienced adult patients. The main clinical ...

This letter was published on May 5, 2020, at NEJM.org. No potential conflict of interest relevant to this letter was reported. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus ...

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist, according to a case series published online Jan. 6 in ...

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

The World Health Organization has discontinued trials of the combination HIV drugs lopinavir and ritonavir as a combined treatment for hospitalized coronavirus patients after interim results showed ...